RU2019131111A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019131111A3 RU2019131111A3 RU2019131111A RU2019131111A RU2019131111A3 RU 2019131111 A3 RU2019131111 A3 RU 2019131111A3 RU 2019131111 A RU2019131111 A RU 2019131111A RU 2019131111 A RU2019131111 A RU 2019131111A RU 2019131111 A3 RU2019131111 A3 RU 2019131111A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710156742.7 | 2017-03-16 | ||
| CN201710156742 | 2017-03-16 | ||
| CN201710982734.8 | 2017-10-20 | ||
| CN201710982734 | 2017-10-20 | ||
| PCT/CN2018/079086 WO2018166493A1 (zh) | 2017-03-16 | 2018-03-15 | 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019131111A RU2019131111A (ru) | 2021-04-16 |
| RU2019131111A3 true RU2019131111A3 (ru) | 2021-04-16 |
| RU2764655C2 RU2764655C2 (ru) | 2022-01-19 |
Family
ID=63523780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019131111A RU2764655C2 (ru) | 2017-03-16 | 2018-03-15 | ПРОИЗВОДНОЕ ГЕТЕРОАРИЛ[4,3-с]ПИРИМИДИН-5-АМИНА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКИЕ ПРИМЕНЕНИЯ |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11312705B2 (ru) |
| EP (1) | EP3575301A4 (ru) |
| JP (1) | JP7111733B2 (ru) |
| KR (1) | KR20190129851A (ru) |
| CN (1) | CN109963854B (ru) |
| AU (1) | AU2018233367B2 (ru) |
| BR (1) | BR112019017108A2 (ru) |
| CA (1) | CA3054976A1 (ru) |
| MX (1) | MX393395B (ru) |
| RU (1) | RU2764655C2 (ru) |
| TW (1) | TWI772386B (ru) |
| UA (1) | UA125592C2 (ru) |
| WO (1) | WO2018166493A1 (ru) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3105226T3 (da) | 2014-02-13 | 2019-10-14 | Incyte Corp | Cyclopropylaminer som lsd1-inhibitorer |
| PT3105218T (pt) | 2014-02-13 | 2019-12-05 | Incyte Corp | Ciclopropilaminas como inibidores de lsd1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| EP3626720A1 (en) | 2015-04-03 | 2020-03-25 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| KR102710120B1 (ko) | 2015-08-12 | 2024-09-27 | 인사이트 홀딩스 코포레이션 | Lsd1 저해제의 염 |
| CN109535161B (zh) * | 2017-09-22 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| MA52422A (fr) * | 2018-02-27 | 2021-01-06 | Incyte Corp | Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b |
| MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
| MA53097A (fr) | 2018-07-05 | 2021-05-12 | Incyte Corp | Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| TWI820209B (zh) | 2018-09-12 | 2023-11-01 | 大陸商迪哲（江蘇）醫藥股份有限公司 | 三唑并－嘧啶化合物及其用途 |
| CN110903291B (zh) * | 2018-09-14 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法 |
| WO2020052648A1 (zh) * | 2018-09-14 | 2020-03-19 | 江苏恒瑞医药股份有限公司 | 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法 |
| CR20210271A (es) | 2018-11-30 | 2021-07-14 | Merck Sharp & Dohme | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso |
| MA54551A (fr) | 2018-12-20 | 2021-10-27 | Incyte Corp | Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine |
| WO2020128036A1 (en) * | 2018-12-21 | 2020-06-25 | Ryvu Therapeutics S.A. | Modulators of the adenosine a2a receptor |
| CA3126735A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| TWI829857B (zh) * | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN111848625B (zh) * | 2019-04-24 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 一种杂芳基并[4,3-c]嘧啶-5-胺类化合物的制备方法及中间体 |
| WO2021156439A1 (en) | 2020-02-06 | 2021-08-12 | Astrazeneca Ab | Triazole compounds as adenosine receptor antagonists |
| KR20230051118A (ko) * | 2020-03-26 | 2023-04-17 | 헵테얼즈 테라퓨틱스 리미티드 | 암에 대해 사용하기 위한 5-아미노-8-(4-피리딜)-[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물 |
| CN115867282B (zh) * | 2020-03-26 | 2025-05-27 | 奈克斯拉制药英国有限公司 | 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物 |
| CN115867550B (zh) * | 2020-03-26 | 2025-01-03 | 奈克斯拉制药英国有限公司 | 三唑酮化合物 |
| WO2021191376A1 (en) | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU743910B2 (en) * | 1997-03-24 | 2002-02-07 | Kyowa Hakko Kirin Co., Ltd. | {1,2,4}triazolo{1,5-c}pyrimidine derivatives |
| ATE286900T1 (de) | 1998-09-22 | 2005-01-15 | Kyowa Hakko Kogyo Kk | (1,2,4)triazolo(1,5-c)pyrimidin-derivate |
| US6355653B1 (en) * | 1999-09-06 | 2002-03-12 | Hoffmann-La Roche Inc. | Amino-triazolopyridine derivatives |
| JP2002037787A (ja) | 2000-05-16 | 2002-02-06 | Kyowa Hakko Kogyo Co Ltd | ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体の製造法 |
| AU2003211993A1 (en) * | 2002-02-15 | 2003-09-04 | Kyowa Hakko Kogyo Co., Ltd. | (1,2,4)TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVES |
| KR100973609B1 (ko) * | 2005-03-23 | 2010-08-03 | 에프. 호프만-라 로슈 아게 | ｍＧｌｕＲ2 길항제로서 아세틸렌일-피라졸로-피리미딘유도체 |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| DE102006008880A1 (de) | 2006-02-27 | 2007-09-06 | Merck Patent Gmbh | Aminopyrimidinderivate |
| WO2007116106A1 (es) | 2006-04-12 | 2007-10-18 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina |
| DE102007061763A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
| AU2009222047A1 (en) | 2008-03-04 | 2009-09-11 | Schering Corporation | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists |
| US8796297B2 (en) | 2009-06-30 | 2014-08-05 | Abbvie Inc. | 4-substituted-2-amino-pyrimidine derivatives |
| JO3090B1 (ar) | 2009-12-11 | 2017-03-15 | Janssen Sciences Ireland Uc | 5- امينو-4- هيدروكسي-بنتويل اميدات |
| US8809525B2 (en) | 2010-02-05 | 2014-08-19 | Heptares Therapeutics Limited | 1,2,4-triazine-4-amine derivatives |
| MX2012013081A (es) | 2010-05-12 | 2013-05-09 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
| UY33452A (es) * | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
| WO2011159302A1 (en) | 2010-06-17 | 2011-12-22 | Janssen Pharmaceutica Nv | Arylindenopyrimidines for treating neurodegenerative and movement disorders while minimizing cardiac toxicity |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| JP5647356B2 (ja) | 2010-10-29 | 2014-12-24 | ファイザー・インク | Ｎ１／Ｎ２−ラクタムアセチル−ＣｏＡカルボキシラーゼ阻害剤 |
| CN103608350B (zh) * | 2011-04-21 | 2015-11-25 | 拜耳知识产权有限责任公司 | 三唑并吡啶类化合物 |
| TW201326170A (zh) * | 2011-12-12 | 2013-07-01 | 拜耳製藥公司 | 經取代之三唑并吡啶 |
| WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| TWI628176B (zh) | 2013-04-04 | 2018-07-01 | 奧利安公司 | 蛋白質激酶抑制劑 |
| WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
| MX373129B (es) | 2014-06-17 | 2020-04-29 | Chiesi Farm Spa | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. |
| ES2722048T3 (es) * | 2014-12-23 | 2019-08-07 | Novartis Ag | Compuestos de triazolopirimidina y usos de los mismos |
| CN109535161B (zh) * | 2017-09-22 | 2021-09-03 | 江苏恒瑞医药股份有限公司 | 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| MA52422A (fr) * | 2018-02-27 | 2021-01-06 | Incyte Corp | Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b |
-
2018
- 2018-03-15 CN CN201880004302.2A patent/CN109963854B/zh active Active
- 2018-03-15 UA UAA201910243A patent/UA125592C2/uk unknown
- 2018-03-15 EP EP18766881.9A patent/EP3575301A4/en not_active Withdrawn
- 2018-03-15 MX MX2019010354A patent/MX393395B/es unknown
- 2018-03-15 JP JP2019548401A patent/JP7111733B2/ja active Active
- 2018-03-15 BR BR112019017108A patent/BR112019017108A2/pt not_active Application Discontinuation
- 2018-03-15 AU AU2018233367A patent/AU2018233367B2/en not_active Ceased
- 2018-03-15 WO PCT/CN2018/079086 patent/WO2018166493A1/zh not_active Ceased
- 2018-03-15 RU RU2019131111A patent/RU2764655C2/ru active
- 2018-03-15 US US16/492,273 patent/US11312705B2/en active Active
- 2018-03-15 CA CA3054976A patent/CA3054976A1/en active Pending
- 2018-03-15 KR KR1020197025674A patent/KR20190129851A/ko not_active Withdrawn
- 2018-03-16 TW TW107109077A patent/TWI772386B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2764655C2 (ru) | 2022-01-19 |
| TW201835083A (zh) | 2018-10-01 |
| TWI772386B (zh) | 2022-08-01 |
| EP3575301A4 (en) | 2020-08-05 |
| CN109963854A (zh) | 2019-07-02 |
| MX393395B (es) | 2025-03-24 |
| MX2019010354A (es) | 2019-10-22 |
| US20210032224A1 (en) | 2021-02-04 |
| JP2020510012A (ja) | 2020-04-02 |
| CA3054976A1 (en) | 2018-09-20 |
| CN109963854B (zh) | 2022-04-12 |
| JP7111733B2 (ja) | 2022-08-02 |
| BR112019017108A2 (pt) | 2020-04-07 |
| WO2018166493A1 (zh) | 2018-09-20 |
| RU2019131111A (ru) | 2021-04-16 |
| UA125592C2 (uk) | 2022-04-27 |
| KR20190129851A (ko) | 2019-11-20 |
| AU2018233367B2 (en) | 2021-08-12 |
| EP3575301A1 (en) | 2019-12-04 |
| AU2018233367A1 (en) | 2019-08-29 |
| US11312705B2 (en) | 2022-04-26 |